

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address of MIMISSI OBER OF PATENTS AND TRADEMARKS www.uspto.gov. 20231

APPLICATION NO	HIING DAH	FTRSE NAMED INVENTOR	ALLORNI Y DOCKILI NO	COZITAZIZITOZ ZO
09 887,403	06 22 2001	Gregor Ceve	500,1013	7718
	90 06/04/2002			
DAVIDSON, DAVIDSON & KAPPEL, LLC 14th Floor 485 Seventh Avenue			EXAMINER	
			COE, SUSAN D	
New York, NY	10018		ART UNIT PAPER NUMBER	
			1651	7
			DATE MAILED: 06/04/2002	. /

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Comments	09/887,493	CEVC, GREGOR					
Office Action Summary	Examiner	Art Unit					
	Susan Coe	1651					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1 704(b).  Status							
1) Responsive to communication(s) filed on							
2a) This action is <b>FINAL</b> . 2b) Thi	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims							
4) Claim(s) 1-7,9,11-14,21-24,26-41 and 44-50 is	Jare pending in the application						
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s)is/are rejected.							
	e subject to restriction and/or ele	ction requirement					
8) Claim(s) 1-7,9,11-14,21-24,26-41 and 44-50 are subject to restriction and/or election requirement.  Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accep	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) latent Application (PTO-152)					
S. Patent and Trademark Office							

Application/Control Number: 09/887,493 Page 2

Art Unit: 1651

## **DETAILED ACTION**

1. The preliminary amendment filed June 22, 2001 has been received and entered.

- 2. Claims 8, 10, 15-20, 25, 42, and 43 have been cancelled.
- 3. Claims 1-7, 9, 11-14, 21-24, 26-41, and 44-50 are currently pending. Please take notice of the election of species <u>requirement</u> beginning on page 4. To be fully responsive, applicant must fulfill this requirement.

## Election/Restrictions

- 4. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-7, 9, 11-14, 21-24, 35-41, and 44-46, drawn to a topical formulation, classified in class 424, subclass 401.
  - II. Claims 26-34, drawn to a method of making a topical formulation, classified in class 424, subclass 401.
  - III. Claims 47-49, drawn to a method for applying corticosteroids, classified in class424, subclass 401.
  - IV. Claim 50, drawn to a method of using a topical composition, classified in class424, subclass 401.

The inventions are distinct, each from the other because of the following reasons:

5. Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the

Art Unit: 1651

product can be made in a different process such as simply mixing the required ingredients together.

- 6. Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a different process such as the injection of steroids to reduce inflammation.
- 7. Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a different process such as the use of steroids to treat rash caused by poison ivy.
- 8. Inventions II, III, and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions. Each invention is drawn to a different method of using or making a composition that contains steroids. These different methods of using and making are distinct.

Application/Control Number: 09/887,493

Art Unit: 1651

Because these inventions are distinct for the reasons given above and the search required for one group is not required for the other groups, restriction for examination purposes as indicated is proper.

- 9. This application contains claims directed to the following patentably distinct species of the claimed invention:
  - A) consistency builder selected from those in claim 5;
  - B) antioxidant selected from those in claim 7;
  - C) antioxidant selected from those in claim 9;
  - D) corticosteroid selection from those in claim 13; and
  - E) use selected from those in claim 50.

If applicant elects group I, applicant is required under 35 U.S.C. 121 to elect a single disclosed species of each A, B, C and D for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. If applicant elects group IV, applicant must elect a species from E. If applicant elects group II or III, no election of species is required. Currently, claims 1-7, 9, 11-14, 21-24, 26-35, 40, 41, and 44-50 are generic.

An example of a proper election is as follows: Group I; species A) pectin; species B) ascorbic acid; species C) ethyl alcohol; species D) alclonetasone.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Art Unit: 1651

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Coe whose telephone number is (703) 306-5823. The examiner can normally be reached on Monday to Thursday from 8:00 to 5:30 and on alternating Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (703) 308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SDC

May 22, 2002

EON B. LANKFORD, JR. PRIMARY EXAMINER